On Monday, the FDA is scheduled to make a decision about NuPathe's
The patch delivers sumatriptan, originally developed by GlaxoSmithKline
But Zelrix isn't like your typical transdermal patch -- such as Glaxo's NicoDerm or Novartis'
The biggest risk for investors when drugs face FDA decisions is in the manufacturing. Unlike clinical trial data that's usually published, investors have essentially no view into that aspect of the approval process. That goes double for an electronic patch, which is considerably more complex to manufacture than a simple small-molecule pill.
Johnson & Johnson
What's your take on Zelrix? Tell us in the comment box below.